Molecular Response enables pharmaceutical partners to realize efficiencies in drug development through use of clinically proven molecular markers. We provide comprehensive clinical trial support services from trial-site sample collection to full clinical analysis.

Molecular Response routinely apply available standard of care clinical information with clinically valid, novel and proprietary molecular markers to develop high-value knowledge for existing pharmaceutical development processes and programs; the result reduces risk of development and allows for the most informed decision-making possible.

Molecular Response uses only validated methodologies and proven technology platforms to test precious clinical specimens from patients treated with investigational agents. And to fast–track therapeutic approval, we translate biomarker tests into diagnostic assays regulated as Laboratory Developed tests (LDT) under CLIA guidelines or In Vitro Diagnostics (IVD) through the FDA.

BioAtla is a protein therapeutic service business and a sister company to BioDuro.  BioAtla’s capabilities span a wide range of protein therapeutic development activities including: antigen production, antibody/protein optimization, humanization, humation, fully human antibody generation, pre-clinical testing and more.

Innovative, proprietary technologies make BioAtla a leading global outsourcing company with operations in San Diego and Beijing.  BioAtla’s dedicated staff has decades of experience in the pharmaceutical and biotechnology fields with a proven reputation for successful product and technology development and commercialization.

Femta Pharmaceuticals is focused on the development of therapeutic monoclonal antibodies for the treatment of various disease states.